Tarsus Pharmaceuticals Inc (TARS): Next-Year EPS Estimate 590.05%
As of 2026-06-04, Tarsus Pharmaceuticals Inc (TARS) has a next-year EPS growth estimate of 590.05%.
On 2026-06-03, analyst consensus for TARS's next-year EPS growth shifted from 589.96% to 590.05% — a positive change of 0.09 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 61.06%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 590.05%
- EPS growth this year
- 61.06%
- EPS next quarter (est)
- -$0.22
- Last price
- $60.34
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 590.05% | 61.06% | -$0.22 | $60.34 |
| 2026-06-03 | 590.05% | 61.06% | -$0.22 | $58.76 |
| 2026-06-02 | 589.96% | 61.06% | -$0.22 | $57.41 |
| 2026-06-01 | 589.96% | 61.06% | -$0.22 | $58.93 |
| 2026-05-31 | 589.96% | 61.06% | -$0.22 | $59.40 |
| 2026-05-28 | 589.96% | 61.06% | -$0.22 | $59.54 |
| 2026-05-27 | 589.96% | 61.06% | -$0.22 | $60.06 |
| 2026-05-26 | 590.26% | 61.08% | -$0.22 | $61.16 |
| 2026-05-25 | 590.26% | 61.08% | -$0.22 | $62.26 |
| 2026-05-24 | 590.26% | 61.08% | -$0.22 | $62.26 |
| 2026-05-21 | 590.26% | 61.08% | -$0.22 | $63.48 |
| 2026-05-20 | 590.26% | 61.08% | -$0.22 | $64.79 |
| 2026-05-19 | 519.14% | 55.50% | -$0.22 | $61.29 |
| 2026-05-18 | 519.14% | 55.50% | -$0.22 | $62.82 |
| 2026-05-17 | 519.14% | 55.50% | -$0.22 | $62.48 |
| 2026-05-14 | 516.96% | 55.50% | -$0.23 | $65.18 |
| 2026-05-13 | 516.96% | 55.50% | -$0.23 | $64.39 |
| 2026-05-12 | 516.96% | 55.50% | -$0.23 | $59.83 |
| 2026-05-11 | 516.96% | 55.50% | -$0.23 | $59.65 |
| 2026-05-10 | 516.96% | 55.50% | -$0.23 | $61.21 |
| 2026-05-07 | 526.08% | 54.87% | -$0.17 | $63.96 |
| 2026-05-06 | 520.53% | 53.62% | -$0.40 | $64.76 |
| 2026-05-05 | 544.65% | 56.13% | -$0.39 | $65.04 |
| 2026-05-04 | 544.65% | 56.13% | -$0.39 | $64.57 |
| 2026-05-03 | 545.45% | 56.21% | -$0.37 | $63.62 |
| 2026-04-30 | 545.45% | 56.21% | -$0.37 | $63.61 |
| 2026-04-29 | 545.45% | 56.21% | -$0.37 | $60.67 |
| 2026-04-28 | 528.52% | 54.80% | -$0.31 | $62.09 |
| 2026-04-27 | 528.52% | 54.80% | -$0.31 | $60.93 |
| 2026-04-26 | 528.52% | 54.80% | -$0.31 | $61.45 |
Recent News
- Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby
- Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026GlobeNewswire
- Tarsus Pharmaceuticals Stock Earns Upgrade To RS RatingInvestor's Business Daily
- TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusGlobeNewswire
- TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Tarsus Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Tarsus Pharmaceuticals Inc (TARS) has a next-year EPS growth estimate of 590.05%, based on analyst consensus.
When was the latest EPS estimate revision for TARS?▾
The most recent revision occurred on 2026-06-03, when analysts adjusted the next-year EPS growth estimate from 589.96% to 590.05%.
What sector and industry does Tarsus Pharmaceuticals Inc belong to?▾
Tarsus Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TARS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Tarsus Pharmaceuticals Inc (TARS) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports